Clinical Trial Update: Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study of 20vPnC in healthy children aged 15 months to 17 years completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20vPnC (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-04-26